Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

Janssen files abiraterone acetate NDS with Health Canada for metastatic, advanced prostate cancer

Janssen Inc. has filed a New Drug Submission (NDS) to Health Canada for the investigational drug abiraterone acetate administered with prednisone for the treatment of metastatic, advanced prostate cancer in patients who have received prior chemotherapy containing a taxane. Submissions for abiraterone acetate have also been filed with health authorities in the United States and Europe.

23 Dec 2010

Baylor Sammons Cancer Center, Sarah Cannon, and Virginia Cancer join Multiple Myeloma Research Consortium

The Multiple Myeloma Research Consortium (MMRC) today announced that it has expanded its clinical research network to include Baylor Charles A. Sammons Cancer Center (Dallas, TX), Sarah Cannon /Research Institute (SCRI, Nashville, TN) and Virginia Cancer Specialists (Fairfax, VA). These new centers join the 13 existing MMRC Member Institutions in promoting and facilitating collaborative research and accelerating drug development in multiple myeloma, an incurable blood cancer.

23 Dec 2010

EMCTO 2011 to provide update on treatment of thoracic malignancies

The number of diagnostic and therapeutic options for patients with thoracic malignancies has markedly increased, allowing for an individualized approach based on the clinical situation and molecular characteristics of the tumor. How to best select among these options for the benefit of the patients within an integrative treatment approach will be at the core of the conference.

23 Dec 2010

Santen files IND for Clinical Data's ATL313 for primary open angle glaucoma and ocular hypertension

Clinical Data, Inc., today announced that Santen Pharmaceutical Co., Ltd., has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for Clinical Data's highly selective adenosine A2A agonist, ATL313, for the indication of primary open angle glaucoma and ocular hypertension.

From Santen Pharmaceutical Co., Ltd. 23 Dec 2010

Myrexis commences Azixa controlled two-arm Phase 2b clinical study in GBM

Myrexis, Inc., a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today announced it has initiated a controlled two-arm Phase 2b clinical study of Azixa (verubulin) as a front-line treatment for glioblastoma multiforme (GBM).

23 Dec 2010

GE Healthcare announces completion of tender offer for Clarient

GE Healthcare, a unit of General Electric Company announced today that it has completed the tender offer by GE's wholly owned subsidiary, Crane Merger Sub, Inc., for all outstanding shares of common and preferred stock of Clarient Inc., a leading player in the fast-growing molecular diagnostics sector. Clarient provides pathologists and oncologists with access to key diagnostic tests that shed light on the complex nature of various cancers.

23 Dec 2010

Photon-based radiation therapy may result in better survival rate in patients with spinal-cord tumor

A study comparing the long-term outcomes of patients with spinal-cord tumors following radiation therapy suggests that certain subsets of patients have better long-term survival.

23 Dec 2010

Tekmira begins patient dosing in TKM-PLK1 phase 1 trail for cancer

Tekmira Pharmaceuticals Corporation, a leading developer of RNA interference therapeutics, announced today it has initiated patient dosing in a Phase 1 human clinical trial for its lead oncology product, TKM-PLK1. TKM-PLK1 targets polo-like kinase 1, or PLK1, a cell cycle protein involved in tumor cell proliferation and a validated oncology target.

22 Dec 2010

Arena, Eisai complete lorcaserin NDA end-of-review meeting with FDA

Arena Pharmaceuticals, Inc. and Eisai Inc. announced today the completion of an end-of-review meeting with the US Food and Drug Administration (FDA) for the lorcaserin New Drug Application (NDA).

22 Dec 2010

Delcath completes NDA submission for chemosaturation system

Delcath Systems, Inc. today announced that the Company has submitted the remaining modules of its 505(b)(2) New Drug Application (NDA) for its proprietary chemosaturation system to the U.S. Food & Drug Administration (FDA). The Company had previously submitted Module 4, consisting of literature based non-clinical data, to the FDA in late April 2010. The Company is seeking an indication for the percutaneous intra-arterial administration of melphalan hydrochloride for use in the treatment of patients with metastatic melanoma in the liver.

22 Dec 2010

Therapies to target self-renewing population of chemotherapy-resistant cells needed

Leukemia patients whose cancers express higher levels of genes associated with cancer stem cells have a significantly poorer prognosis than patients with lower levels of the genes, say researchers at the Stanford University School of Medicine. The finding is among the first to show that the cancer stem cell hypothesis - which posits that some cancers spring from and are replenished by a small, hardy population of self-renewing cells - can be used to predict outcomes in a large group of patients and one day to tailor treatments in the clinic.

22 Dec 2010

Men above age 75 with high-risk prostate cancer often under-treated

Older men with high-risk prostate cancer frequently are offered fewer - and less effective - choices of treatment than younger men, potentially resulting in earlier deaths, according to a new UCSF study.

22 Dec 2010

URI, R.I. Hospital to offer medical physics degree

Students interested in physics and medicine will be able to combine disciplines to become medical physicists and enter an expanding field that offers multiple career opportunities and salaries that start with six figures.

21 Dec 2010

ICU Medical wins I.V. connector patent infringement suit against RyMed

ICU Medical, Inc., a leading manufacturer of safe medical connectors, custom medical products and critical care devices, recently secured a victory in a patent infringement case against RyMed Technologies, Inc.

21 Dec 2010

Biovest issues FAQ update on BiovaxID personalized cancer vaccine

Biovest International, Inc. today issued the following update in the form of a "Frequently Asked Questions" report in response to the high volume of inquiries received following the Company's recent presentation at the 2010 American Society of Hematology Annual Meeting (ASH 2010) in Orlando, Florida.

21 Dec 2010

Poniard completes voluntary prepayment of $12.35 million under senior secured loan facility

Poniard Pharmaceuticals, Inc., a biopharmaceutical company focused on innovative oncology therapies, announced today that it has completed the voluntary prepayment of the $12.35 million aggregate principal, interest and fees due under its senior secured loan facility with GE Business Financial Services Inc. and Silicon Valley Bank.

21 Dec 2010

Dentists recognized for excellence in ethics, leadership and professionalism

Two local dentists were recently recognized for excellence in ethics, leadership and professionalism when they were invited to become Fellows of the American College of Dentists.

21 Dec 2010

Exiqon completes discovery phase program for early detection of colorectal cancer in blood

Exiqon A/S today announced the completion of the discovery phase in its program for early detection of colorectal cancer in blood.

21 Dec 2010

Recent study finds racial and ethnic minority smokers of menthol cigarettes have lower quit rate

Menthol cigarettes may be harder to quit, particularly for some teens and African-Americans, who have the highest menthol cigarette use, according to a study by a team of researchers.

21 Dec 2010

ExonHit awarded QTDP grants for AclarusDx and EHT 107 programs

ExonHit Therapeutics today announced that the Company was awarded two grants to support two of its Research & Development projects under the Qualifying Therapeutic Discovery Project Program: AclarusDx™ in Alzheimer's disease and the EHT 107 program in oncology.

21 Dec 2010

Oncology News and Research

Further Reading

Janssen files abiraterone acetate NDS with Health Canada for metastatic, advanced prostate cancer

Baylor Sammons Cancer Center, Sarah Cannon, and Virginia Cancer join Multiple Myeloma Research Consortium

EMCTO 2011 to provide update on treatment of thoracic malignancies

Santen files IND for Clinical Data's ATL313 for primary open angle glaucoma and ocular hypertension

Myrexis commences Azixa controlled two-arm Phase 2b clinical study in GBM

GE Healthcare announces completion of tender offer for Clarient

Photon-based radiation therapy may result in better survival rate in patients with spinal-cord tumor

Tekmira begins patient dosing in TKM-PLK1 phase 1 trail for cancer

Arena, Eisai complete lorcaserin NDA end-of-review meeting with FDA

Delcath completes NDA submission for chemosaturation system

Therapies to target self-renewing population of chemotherapy-resistant cells needed

Men above age 75 with high-risk prostate cancer often under-treated

URI, R.I. Hospital to offer medical physics degree

ICU Medical wins I.V. connector patent infringement suit against RyMed

Biovest issues FAQ update on BiovaxID personalized cancer vaccine

Poniard completes voluntary prepayment of $12.35 million under senior secured loan facility

Dentists recognized for excellence in ethics, leadership and professionalism

Exiqon completes discovery phase program for early detection of colorectal cancer in blood

Recent study finds racial and ethnic minority smokers of menthol cigarettes have lower quit rate

ExonHit awarded QTDP grants for AclarusDx and EHT 107 programs

Event guide: The 9th DDR Inhibitors Summit 2026 eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News